Final results of the EORTC Brain Tumor Group randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1st recurrence grade II/III glioma without 1p/19q co-deletion.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Clinical Oncology

• Publication date

  2017-05-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2017.35.15_SUPPL.2009
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Clinical characteristics and overall survival prognostic nomogram for oligodendroglioma: a SEER population-based analysis.

  2021cites this paper
• Modern Treatments for Gliomas Improve Outcome

  2020cites this paper
• Updates Treatment of Low-Grade Glioma

  2020cites this paper
• The Ever Changing Treatments for Tumors of the Central Nervous System

  2020cites this paper
• INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

  2019cites this paper
• WHO II and III Gliomas

  2019cites this paper
• Current therapeutic approaches to diffuse grade II and III gliomas

  2018cites this paper
• Anti-angiogenic therapy for high-grade glioma.

  2018cites this paper
• Management of diffuse glioma.

  2018cites this paper
• Grade II and III Oligodendroglioma and Astrocytoma.

  2018cites this paper